Clinical Trial Update: 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing the investigational agent 601 with ranibizumab in Central Retinal Vein Occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion

Drugs mentioned

• 601
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Central Retinal Vein Occlusion | Phase 2 | Status: COMPLETED